Wang Changbing, Chen Haiyang, Chen Danyang, Zhao Mingqi, Lin Zhengfang, Guo Min, Xu Tiantian, Chen Yi, Hua Liang, Lin Tao, Tang Ying, Zhu Bing, Li Yinghua
Center Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No 318 Renminzhong Road, Yuexiu District, Guangzhou 510120, Guangdong, People's Republic of China.
ACS Omega. 2020 Nov 16;5(47):30633-30642. doi: 10.1021/acsomega.0c04624. eCollection 2020 Dec 1.
β-Thujaplicin possess a variety of biological activities. The use of modified biological nanoparticles (NPs) to develop novel anti-influenza drugs has increased in recent years. Selenium nanoparticles (SeNPs) with antiviral activity have attracted increasing attention for biomedical intervention. Functionalized SeNPs by β-thujaplicin (Se@TP) surface modified with superior antiviral activity were synthesized in this study. Compared to a virus group (43%), when treated with Se@TP (88%), the cell survival rate of MDCK cells was 45% higher. Se@TP could inhibit H1N1 from infecting Madin-Darby canine kidney (MDCK) cells and block chromatin condensation and DNA fragmentation. Se@TP obviously prevented MDCK cells from generating reactive oxygen species. Furthermore, Se@TP prevents lung injury in H1N1-infected mice through eosin staining and hematoxylin . Mechanistic investigation revealed that Se@TP inhibited H1N1 influenza virus from infecting MDCK cells through induction of apoptosis via suppressing AKT and p53 signaling pathways through immunohistochemical assay. Our results suggest that β-thujaplicin-modified SeNPs as carriers are an efficient way to achieve an antiviral pharmaceutical candidate for H1N1 influenza.
β-崖柏素具有多种生物活性。近年来,利用改性生物纳米颗粒(NPs)开发新型抗流感药物的研究日益增多。具有抗病毒活性的硒纳米颗粒(SeNPs)在生物医学干预方面受到越来越多的关注。本研究合成了用β-崖柏素表面改性的具有优异抗病毒活性的功能化硒纳米颗粒(Se@TP)。与病毒组(43%)相比,用Se@TP处理时(88%),MDCK细胞的细胞存活率高出45%。Se@TP可抑制H1N1感染麦迪逊-达比犬肾(MDCK)细胞,并阻止染色质浓缩和DNA片段化。Se@TP明显可防止MDCK细胞产生活性氧。此外,Se@TP通过伊红染色和苏木精染色可防止H1N1感染小鼠的肺损伤。机制研究表明,Se@TP通过免疫组织化学分析抑制H1N1流感病毒感染MDCK细胞,通过抑制AKT和p53信号通路诱导细胞凋亡。我们的研究结果表明,β-崖柏素改性的SeNPs作为载体是获得H1N1流感抗病毒药物候选物的有效途径。